GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding GRI Bio, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 13 | 10 | −3 |
| Shares | 406.9K | 222.0K | −184.9K (−45.4%) |
| Value | $765.0K | $141.0K | −$624.0K (−81.6%) |
New holders (3)
Institutions that held GRI Bio, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 78,888 | $50.0K | 0.00% |
| Two Sigma Investments, LP | 42,392 | $27.0K | 0.00% |
| Susquehanna International Group, LLP | 35,798 | $23.0K | 0.00% |
Sold out (6)
Institutions that held GRI Bio, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ikarian Capital, LLC | 201,758 | $380.0K |
| Boothbay Fund Management, LLC | 21,250 | $40.0K |
| Zeke Capital Advisors, LLC | 15,000 | $28.0K |
| Jane Street Group, LLC | 14,920 | $28.0K |
| UBS Group AG | 8,794 | $17.0K |
| Advisor Group Holdings, Inc. | 2,364 | $4.00K |